Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 17/20 | 0.86 |
| ▸ | AKR1C3 | P42330 | 2/20 | 0.83 |
| ▸ | CNR2 | P34972 | 1/20 | 0.83 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.82 |
| ▸ | GLO1 | Q04760 | 2/20 | 0.82 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.82 |
| ▸ | HTR1A | P08908 | 1/20 | 0.82 |
| ▸ | PKM | P14618 | 1/20 | 0.82 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.77 |
| ▸ | MEN1 | O00255 | 1/20 | 0.77 |
| ▸ | PTGES | O14684 | 1/20 | 0.77 |
| ▸ | ABCC3 | O15438 | 1/20 | 0.77 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.77 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.77 |
| ▸ | MT-CO2 | P00403 | 1/20 | 0.77 |
| ▸ | LMNA | P02545 | 1/20 | 0.77 |
| ▸ | ALB | P02768 | 1/20 | 0.77 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.77 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.77 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.77 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29855593 | 1.00 | PTGS2 (0.86) | PTGS2AKR1C3CNR2PTGS1GLO1 | |
| SCHEMBL4549122 | 0.93 | PTGS2 (1.00) | PTGS2AKR1C3CNR2PTGS1GLO1 | |
| SCHEMBL30426824 | 0.91 | PTGS2 (1.00) | PTGS2AKR1C3CNR2PTGS1GLO1 | |
| SCHEMBL14086813 | 0.91 | PTGS2 (1.00) | PTGS2AKR1C3CNR2PTGS1GLO1 | |
| SCHEMBL11092811 | 0.91 | PTGS2 (0.88) | PTGS2AKR1C3CNR2PTGS1GLO1 | |
| SCHEMBL12742120 | 0.90 | PTGS2 (0.91) | PTGS2AKR1C3CNR2PTGS1GLO1 | |
| SCHEMBL12609003 | 0.90 | PTGS2 (0.85) | PTGS2AKR1C3CNR2PTGS1GLO1 | |
| Acemetacin SCHEMBL23843 | 0.90 | PTGS2 (1.00) | PTGS2AKR1C3CNR2PTGS1GLO1 | |
| SCHEMBL11174704 | 0.90 | PTGS2 (0.85) | PTGS2AKR1C3CNR2PTGS1GLO1 | |
| Acemetacin SCHEMBL29402955 | 0.90 | PTGS2 (1.00) | PTGS2AKR1C3CNR2PTGS1GLO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9359376-B2 | Substituted methylformyl reagents and method of using same to modify physicochemical and/or pharmacokinetic properties of compounds | SPHAERA PHARMA PTE. LTD (SG) | 2016-06-07 | — | — | US | claimed |
| US-20140121367-A1 | SUBSTITUTED METHYLFORMYL REAGENTS AND METHOD OF USING SAME TO MODIFY PHYSICOCHEMICAL AND/OR PHARMACOKINETIC PROPERTIES OF COMPOUNDS | PIVOT HOLDING LLC | 2014-05-01 | — | — | US | claimed |
| EP-2693876-A1 | SUBSTITUTED METHYLFORMYL REAGENTS AND METHOD OF USING SAME TO MODIFY PHYSICOCHEMICAL AND/OR PHARMACOKINETIC PROPERTIES OF COMPOUNDS | Sphaera Pharma Pte. Ltd (SG) | 2014-02-12 | — | — | EP | claimed |
| WO-2012137225-A1 | SUBSTITUTED METHYLFORMYL REAGENTS AND METHOD OF USING SAME TO MODIFY PHYSICOCHEMICAL AND/OR PHARMACOKINETIC PROPERTIES OF COMPOUNDS | SPHAERA PHARMA PVT. LTD (IN) | 2012-10-11 | — | — | WO | claimed |
| US-9359376-B2 | Substituted methylformyl reagents and method of using same to modify physicochemical and/or pharmacokinetic properties of compounds | SPHAERA PHARMA PTE. LTD (SG) | 2016-06-07 | — | — | US | disclosed |
| US-9359376-B2 | Substituted methylformyl reagents and method of using same to modify physicochemical and/or pharmacokinetic properties of compounds | SPHAERA PHARMA PTE. LTD (SG) | 2016-06-07 | — | — | US | disclosed |
| US-9359376-B2 | Substituted methylformyl reagents and method of using same to modify physicochemical and/or pharmacokinetic properties of compounds | SPHAERA PHARMA PTE. LTD (SG) | 2016-06-07 | — | — | US | disclosed |
| US-20140121367-A1 | SUBSTITUTED METHYLFORMYL REAGENTS AND METHOD OF USING SAME TO MODIFY PHYSICOCHEMICAL AND/OR PHARMACOKINETIC PROPERTIES OF COMPOUNDS | PIVOT HOLDING LLC | 2014-05-01 | — | — | US | disclosed |
| EP-2693876-A1 | SUBSTITUTED METHYLFORMYL REAGENTS AND METHOD OF USING SAME TO MODIFY PHYSICOCHEMICAL AND/OR PHARMACOKINETIC PROPERTIES OF COMPOUNDS | Sphaera Pharma Pte. Ltd (SG) | 2014-02-12 | — | — | EP | disclosed |
| WO-2012137225-A1 | SUBSTITUTED METHYLFORMYL REAGENTS AND METHOD OF USING SAME TO MODIFY PHYSICOCHEMICAL AND/OR PHARMACOKINETIC PROPERTIES OF COMPOUNDS | SPHAERA PHARMA PVT. LTD (IN) | 2012-10-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140121367-A1 | SUBSTITUTED METHYLFORMYL REAGENTS AND METHOD OF USING SAME TO MODIFY PHYSICOCHEMICAL AND/OR PHARMACOKINETIC PROPERTIES OF COMPOUNDS | TPMT, BHMT2, PFAS | PTGS2 1821/4885AKR1C3 892/4885CNR2 1466/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.